PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15246889-6	2004	Rosiglitazone treatment significantly reduced C-reactive protein (median 0.56 mg/L [interquartile range 0.33 to 1.02] to 0.33 mg/L [interquartile range 0.26 to 0.40], p <0.01), von Willebrand factor (139 +/- 47 to 132 +/- 44 IU/dl, p = 0.02), insulin resistance index (p = 0.05), and mean low-density lipoprotein (LDL) density (p <0.001) compared with placebo.	Rosiglitazone	0-13	von Willebrand factor	Homo sapiens	180-230	
18035190-17	2007	In the GLY+RSG group, there were significant improvements in tPA (-17.8%; P < 0.001), vWF (-11.3%; P = 0.019), and UACR (-17.2%; P = 0.028) over 24 weeks" treatment, whereas there were no significant changes in any of these factors in the GLY+PBO group.	Rosiglitazone	11-14	von Willebrand factor	Homo sapiens	89-92	
25897968-8	2015	Subgroup analyses of PAI-1, vWF% and fibrinogen in terms of trial drugs showed significant reductions for rosiglitazone (all p valuses< 0.05), but not pioglitazone treatment.	Rosiglitazone	106-119	von Willebrand factor	Homo sapiens	28-32